Cargando…

Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study

The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step-down treatment with budesonide...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhimin, Bian, Xiangli, Hui, Lei, Zhang, Jinping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027130/
https://www.ncbi.nlm.nih.gov/pubmed/32104218
http://dx.doi.org/10.3892/etm.2019.8401
_version_ 1783498806705258496
author Wu, Zhimin
Bian, Xiangli
Hui, Lei
Zhang, Jinping
author_facet Wu, Zhimin
Bian, Xiangli
Hui, Lei
Zhang, Jinping
author_sort Wu, Zhimin
collection PubMed
description The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step-down treatment with budesonide step-down treatment in infantile asthma. The data of 778 infants with confirmed asthma were included in the analysis. Infants who had received nebulized 500 µg budesonide twice daily for 6 weeks followed by 250 µg budesonide twice daily for 6 weeks were included in the BS group (n=389), while infants who had received nebulized 250 µg fluticasone twice daily for 6 weeks followed by 125 µg fluticasone twice daily for 6 weeks were included in the FC group (n=389). The data of lung function tests and a safety study were collected and analyzed. Budesonide treatment achieved a reduced specific airway resistance (sRaw; 1.28±0.11 vs. 1.21±0.10 kPa/sec; P<0.0001, q=13.45) and improved forced expiratory volume in 1 sec (FEV1; 0.977±0.068 vs. 0.997±0.085 l/sec; P<0.0001, q=5.54). In addition, fluticasone treatment achieved a reduced sRaw (1.27±0.1 vs. 1.23±0.11 kPa/sec, P<0.0001, q=7.39) and improved FEV1 (0.971±0.069 vs. 0.992±0.085 l/sec; P=0.0003, q=5.46). Of note, the efficacy of budesonide to reduce sRaw (P=0.008, q=3.69) and improve FEV1 (P<0.0001, q=6.93) was greater than that of fluticasone. The budesonide treatment group had more post-treatment symptom-free days than the fluticasone treatment group (165.56±23.15 vs. 112.21±9.45 days; P<0.0001). The step-down approach of budesonide nebulization may better support the functional and clinical outcomes with an increased number of post-treatment symptom-free days compared with fluticasone in infantile asthma (level of evidence, 3).
format Online
Article
Text
id pubmed-7027130
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70271302020-02-26 Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study Wu, Zhimin Bian, Xiangli Hui, Lei Zhang, Jinping Exp Ther Med Articles The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step-down treatment with budesonide step-down treatment in infantile asthma. The data of 778 infants with confirmed asthma were included in the analysis. Infants who had received nebulized 500 µg budesonide twice daily for 6 weeks followed by 250 µg budesonide twice daily for 6 weeks were included in the BS group (n=389), while infants who had received nebulized 250 µg fluticasone twice daily for 6 weeks followed by 125 µg fluticasone twice daily for 6 weeks were included in the FC group (n=389). The data of lung function tests and a safety study were collected and analyzed. Budesonide treatment achieved a reduced specific airway resistance (sRaw; 1.28±0.11 vs. 1.21±0.10 kPa/sec; P<0.0001, q=13.45) and improved forced expiratory volume in 1 sec (FEV1; 0.977±0.068 vs. 0.997±0.085 l/sec; P<0.0001, q=5.54). In addition, fluticasone treatment achieved a reduced sRaw (1.27±0.1 vs. 1.23±0.11 kPa/sec, P<0.0001, q=7.39) and improved FEV1 (0.971±0.069 vs. 0.992±0.085 l/sec; P=0.0003, q=5.46). Of note, the efficacy of budesonide to reduce sRaw (P=0.008, q=3.69) and improve FEV1 (P<0.0001, q=6.93) was greater than that of fluticasone. The budesonide treatment group had more post-treatment symptom-free days than the fluticasone treatment group (165.56±23.15 vs. 112.21±9.45 days; P<0.0001). The step-down approach of budesonide nebulization may better support the functional and clinical outcomes with an increased number of post-treatment symptom-free days compared with fluticasone in infantile asthma (level of evidence, 3). D.A. Spandidos 2020-03 2019-12-31 /pmc/articles/PMC7027130/ /pubmed/32104218 http://dx.doi.org/10.3892/etm.2019.8401 Text en Copyright: © Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wu, Zhimin
Bian, Xiangli
Hui, Lei
Zhang, Jinping
Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title_full Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title_fullStr Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title_full_unstemmed Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title_short Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
title_sort nebulized step-down budesonide vs. fluticasone in infantile asthma: a retrospective cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027130/
https://www.ncbi.nlm.nih.gov/pubmed/32104218
http://dx.doi.org/10.3892/etm.2019.8401
work_keys_str_mv AT wuzhimin nebulizedstepdownbudesonidevsfluticasoneininfantileasthmaaretrospectivecohortstudy
AT bianxiangli nebulizedstepdownbudesonidevsfluticasoneininfantileasthmaaretrospectivecohortstudy
AT huilei nebulizedstepdownbudesonidevsfluticasoneininfantileasthmaaretrospectivecohortstudy
AT zhangjinping nebulizedstepdownbudesonidevsfluticasoneininfantileasthmaaretrospectivecohortstudy